Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes

Diabetologia

Volumn 58, Issue 7, 2015, Pages 1430-1435

  Thurber, Brian W ^a   Carmody, David ^a   Tadie, Elizabeth C ^a   Pastore, Ashley N ^a   Dickens, Jazzmyne T ^a   Wroblewski, Kristen E ^a   Naylor, Rochelle N ^a   Philipson, Louis H ^a   Greeley, Siri Atma W ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Dosing; Glibenclamide; Glyburide; HbA1c; KATP channel; KCNJ11; Monogenic diabetes; Neonatal diabetes; Pharmacotherapy; Sulfonylurea

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; C PEPTIDE; GLIBENCLAMIDE; HEMOGLOBIN A1C; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; INWARDLY RECTIFYING POTASSIUM CHANNEL; SULFONYLUREA DERIVATIVE;

AGE; ANEMIA; ANGINA PECTORIS; ARTICLE; COHORT ANALYSIS; DIARRHEA; DRUG ERUPTION; ELECTROLYTE DISTURBANCE; FEMALE; GENE MUTATION; GENETIC CODE; GENETIC SCREENING; HEART ARRHYTHMIA; HETEROZYGOTE; HUMAN; HYPOGLYCEMIA; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LEUKOPENIA; LONGITUDINAL STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEWBORN; NEWBORN DIABETES MELLITUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TIME TO TREATMENT; TOOTH DISCOLORATION; TREATMENT OUTCOME; VOMITING; ADOLESCENT; ADULT; CHILD; DIABETES MELLITUS; DOSE RESPONSE; GENETICS; INFANT; MUTATION; ONSET AGE; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGE OF ONSET; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFANT; INFANT, NEWBORN; MALE; MUTATION; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84931577629     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3593-9     Document Type: Article

References (29)

1. Zung A, Glaser B, Nimri R, Zadik Z (2004) Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. J Clin Endocrinol Metab 89:5504–5507
2. Pearson ER, Flechtner I, Njølstad PR et al (2006) Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 355:467–477
3. Rafiq M, Flanagan SE, Patch A-M et al (2008) Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care 31:204–209
4. Proks P, Antcliff JF, Lippiat J, Gloyn AL, Hattersley AT, Ashcroft FM (2004) Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features. Proc Natl Acad Sci U S A 101:17539–17544
5. Hattersley AT (2005) Molecular genetics goes to the diabetes clinic. Clin Med 5:476–481
6. Greeley SAW, Tucker SE, Naylor RN, Bell GI, Philipson LH (2010) Neonatal diabetes mellitus: a model for personalized medicine. Trends Endocrinol Metab 21:464–472
7. Bonnefond A, Durand E, Sand O et al (2010) Molecular diagnosis of neonatal diabetes mellitus using next-generation sequencing of the whole exome. PLoS ONE 5:e13630
8. Edghill EL, Flanagan SE, Ellard S (2010) Permanent neonatal diabetes due to activating mutations in ABCC8 and KCNJ11. Rev Endocr Metab Disord 11:193–198
9. Ashcroft FM (2005) ATP-sensitive potassium channelopathies: focus on insulin secretion. J Clin Invest 115:2047–2058
10. Flanagan SE, Clauin S, Bellanné-Chantelot C et al (2009) Update of mutations in the genes encoding the pancreatic beta-cell K(ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum Mutat 30:170–180
11. McTaggart JS, Clark RH, Ashcroft FM (2010) The role of the KATP channel in glucose homeostasis in health and disease: more than meets the islet. J Physiol Lond 588:3201–3209
12. Greeley SAW, Naylor RN, Cook LS, Tucker SE, Lipton RB, Philipson LH (2011) Creation of the Web-based University of Chicago Monogenic Diabetes Registry: using technology to facilitate longitudinal study of rare subtypes of diabetes. J Diabetes Sci Technol 5:879–886
13. Gloyn AL, Reimann F, Girard C et al (2005) Relapsing diabetes can result from moderately activating mutations in KCNJ11. Hum Mol Genet 14:925–934
14. Masia R, Koster JC, Tumini S et al (2007) An ATP-binding mutation (G334D) in KCNJ11 is associated with a sulfonylurea-insensitive form of developmental delay, epilepsy, and neonatal diabetes. Diabetes 56:328–336
15. Manna Della T, Battistim C, Radonsky V et al (2008) Glibenclamide unresponsiveness in a Brazilian child with permanent neonatal diabetes mellitus and DEND syndrome due to a C166Y mutation in KCNJ11 (Kir6.2) gene. Arq Bras Endocrinol Metabol 52:1350–1355
16. Bell DSH (2004) Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy. Clin Ther 26:1714–1727
17. 1c measurements in infants. Pediatr Diabetes 14:267–272
18. Støy J, Greeley SAW, Paz VP et al (2008) Diagnosis and treatment of neonatal diabetes: a United States experience. Pediatr Diabetes 9:450–459
19. Klupa T, Skupien J, Mirkiewicz-Sieradzka B et al (2010) Efficacy and safety of sulfonylurea use in permanent neonatal diabetes due to KCNJ11 gene mutations: 34-month median follow-up. Diabetes Technol Ther 12:387–391
20. Iafusco D, Bizzarri C, Cadario F et al (2011) No beta cell desensitisation after a median of 68 months on glibenclamide therapy in patients with KCNJ11-associated permanent neonatal diabetes. Diabetologia 54:2736–2738
21. Gregg BE, Moore PC, Demozay D et al (2012) Formation of a human β-cell population within pancreatic islets is set early in life. J Clin Endocrinol Metab 97:3197–3206
22. Gloyn AL, Pearson ER, Antcliff JF et al (2004) Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 350:1838–1849
23. Hannon TS, Janosky J, Arslanian SA (2006) Longitudinal study of physiologic insulin resistance and metabolic changes of puberty. Pediatr Res 60:759–763
24. Moran A, Jacobs DR, Steinberger J et al (1999) Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes 48:2039–2044
25. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853
26. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986
27. Nathan DM, DCCT/EDIC Research Group (2014) The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care 37:9–16
28. Greeley SAW, John PM, Winn AN et al (2011) The cost-effectiveness of personalized genetic medicine: the case of genetic testing in neonatal diabetes. Diabetes Care 34:622–627
29. Carmody D, Bell CD, Hwang JL et al (2014) Sulfonylurea treatment before genetic testing in neonatal diabetes: pros and cons. J Clin Endocrinol Metab 99:e2709–e2714